Phase 2 treatment results demonstrate reduction in CMV burden by all LR methods.

CMV DNA titer by QA-PCR (GE/mL). (A) S indicates positive screening test immediately before entry into phase 2; DA, donor titer immediately before apheresis donation; A, apheresis product titer. (B) DW indicates donor titer immediately before whole blood donation; FP, titer in filtered platelets prepared from whole blood; FR, titer in filtered RBCs prepared from whole blood. Median values are indicated by horizontal bar and arrow. Minimum detection level 100 GE/mL from peripheral blood (S, DA, DW) and 4 GE/mL for final products (A, FP, FR).